SCHEMBL1201233

SCHEMBL1201233

NCCC(O)c1cccs1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
KMT2A Q03164 1/20 0.51
HTR1A P08908 2/20 0.44
SLC6A2 P23975 2/20 0.44
SLC6A4 P31645 2/20 0.44
SLC6A3 Q01959 1/20 0.44
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
KEAP1 Q14145 1/20 0.42
TAAR1 Q96RJ0 1/20 0.41
SLC7A5 Q01650 1/20 0.39
SLC5A2 P31639 1/20 0.39
ALOX5 P09917 1/20 0.39
TSHR P16473 1/20 0.39
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5684870 1.00 NPC1 (0.51) NPC1RAB9AKMT2AHTR1ASLC6A2
Hydrochloric Acid SCHEMBL5447489 0.98 NPC1 (0.50) NPC1RAB9AKMT2AHTR1ASLC6A2
SCHEMBL4440609 0.87 NPC1 (0.57) NPC1RAB9AKMT2AHTR1ACES2
SCHEMBL4131049 0.83
SCHEMBL3229012 0.82 NPC1 (0.53) NPC1RAB9AKMT2AHTR1ASLC6A2
SCHEMBL14525329 0.82 NPC1 (0.53) NPC1RAB9AKMT2AHTR1ASLC6A2
SCHEMBL7277256 0.80 NPC1 (0.46) NPC1RAB9AKMT2AHTR1ASLC6A2
Methylamine SCHEMBL6327312 0.80 SLC6A2 (0.47) NPC1RAB9AKMT2AHTR1ASLC6A2
SCHEMBL1200723 0.80 NPC1 (0.55) NPC1RAB9AKMT2AHTR1ACES2
SCHEMBL1232311 0.80 NPC1 (0.55) NPC1RAB9AKMT2AHTR1ACES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107488163-A The preparation method of (2 thienyl) 1 propyl alcohol of one kind (S) 3 N, N disubstituted amidos 1 天台宜生生化科技有限公司 2017-12-19 CN claimed
US-7893281-B2 Process for preparing arylaminopropanols LANXESS DEUTSCHLAND GMBH (DE) 2011-02-22 US claimed
US-20090286997-A1 PROCESS FOR PREPARING ARYLAMINOPROPANOLS LANXESS DEUTSCHLAND GMBH (DE) 2009-11-19 US claimed
EP-2060559-A1 Process for the preparation of enantiomerically pure 3-hydroxy-3-arylpropylamines and their optical stereoisomers Cadila Pharmaceuticals Limited (IN) 2009-05-20 EP claimed
CN-101012220-A Method of preparing N-methyl-3-hydroxy-3-(2-thiophene)propylamine UNIV TIANJIN (CN) 2007-08-08 CN claimed
US-20050107621-A1 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same MITSUBISHI CHEMICAL CORPORATION (JP) 2005-05-19 US claimed
EP-1486493-A1 3-HYDROXY-3-(2-THIENYL)PROPIONAMIDE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND PROCESS FOR PRODUCING 3-AMINO-1-(2-THIENYL)-1-PROPANOL COMPOUND THEREFROM Mitsubishi Chemical Corporation (JP) 2004-12-15 EP claimed
WO-2004031168-A2 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF OPTICALLY ACTIVE 3-AMINO-1-(2-THIENYL)-1-PROPANOL DERIVATIVES LONZA AG (CH) 2004-04-15 WO claimed
CN-114437022-A Preparation method of duloxetine intermediate 浙江拓普药业股份有限公司 2022-05-06 CN disclosed
US-20200087249-A1 Inhibitors of Quorum Sensing Receptor LasR WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2020-03-19 US disclosed
US-20190119201-A1 Inhibitors of Quorum Sensing Receptor LasR WISCONSIN ALUMNI RESEARCH FOUNDATION 2019-04-25 US disclosed
CN-109485634-A A kind of preparation method of S- (+) duloxetine hydrochloride intermediate 成都倍特药业有限公司 2019-03-19 CN disclosed
CN-107488163-A The preparation method of (2 thienyl) 1 propyl alcohol of one kind (S) 3 N, N disubstituted amidos 1 天台宜生生化科技有限公司 2017-12-19 CN disclosed
CN-105274069-A Alcohol dehydrogenase and uses thereof in synthesis of Duloxetine intermediate NANJING ABIOCHEM BIOMEDICAL TECHNOLOGY CO LTD 2016-01-27 CN disclosed
US-20030171592-A1 Process for producing optically active amino alcohols and intermediates therefore KANTO KAGAKU KABUSHIKI KAISHA (JP) 2003-09-11 US disclosed
WO-2003070720-A1 PREPARATION OF N-METHYL-3-HYDROXY- 3-(2-THIENYL)PROPYLAMINE VIA NOVEL THIOPHENE DERIVATIVES CONTAINING CARBAMATE GROUPS AS INTERMEDIATES DEGUSSA AG (DE) 2003-08-28 WO disclosed
EP-1308435-A2 Process for producing optically active amino alcohols Kanto Kagaku Kabushiki Kaisha (JP) 2003-05-07 EP disclosed
EP-0648768-B1 Preparation of 3-dihaloacetyl oxazolidines MONSANTO CO (US) 1997-11-26 EP disclosed
US-5428172-A Preparation of 3-dihaloacetyl oxazolidines MONSANTO COMPANY (US) 1995-06-27 US disclosed
EP-0648768-A1 Preparation of 3-dihaloacetyl oxazolidines MONSANTO COMPANY (US) 1995-04-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107621-A1 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same APEH, AADAC, KMO NPC1 3667/4885RAB9A 3805/4885KMT2A 1564/4885
US-20030171592-A1 Process for producing optically active amino alcohols and intermediates therefore ADH1A, NOS1, ADH5 NPC1 3259/4885RAB9A 2501/4885KMT2A 1865/4885
US-20200087249-A1 Inhibitors of Quorum Sensing Receptor LasR FFAR1, CYSLTR1, LPAR1 NPC1 3275/4885RAB9A 2781/4885KMT2A 3939/4885
US-20090286997-A1 PROCESS FOR PREPARING ARYLAMINOPROPANOLS AHR, CYP1A1, CYP1A2 NPC1 2343/4885RAB9A 3297/4885KMT2A 746/4885
US-20190119201-A1 Inhibitors of Quorum Sensing Receptor LasR FFAR1, CYSLTR1, LPAR1 NPC1 3275/4885RAB9A 2781/4885KMT2A 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.